Multiple Myeloma
Key Points
Key Points
The estimated number of deaths from multiple myeloma in 2018 is 12,770, representing 2.1% of all cancer deaths.
Despite significant advances and improvements in overall survival, multiple myeloma remains incurable and additional treatments are needed.
The median survival is just over 5 years and most patients receive 4 or more different lines of therapy throughout their disease course.
Treatment
Treatm...
...lant Eligible...
...hould be referred to a transplant center to det...
...ge and renal function should not be the sol...
...regimen and number of cycles remai...
...front transplant should be offered to...
...ed with stem cell toxicity, such as mel...
...ell collection (sufficient for more than one...
...evel of minimal response required to procee...
High-dose melphalan is the recommended condit...
...gous SCT should not be routinely recommended....
...age or delayed SCT may be used as consolidat...
...transplant for multiple myeloma is no...
...herapy is not routinely recommended but may b...
...alidomide maintenance therapy should be routinely...
...tolerant of or unable to receive lenalido...
...risk patients, maintenance therapy with...
...here is insufficient evidence to make modifi...
...he quality and depth of response should be...
...of initial therapy for transplant eligible p...
...s recommended that depth of response be...
...-body low dose CT scan has been shown t...
...lant Ineligible...
...itial treatment recommendations for...
...ent for patients with multiple myeloma wh...
...et therapies for patients with mult...
...hysicians/patients should balance the potential im...
...us therapy should be offered over fixed duration...
...l of initial therapy for transplant ineli...
...esponse for all patients should be assessed by...
...cient evidence to support change i...
Upon initiation of therapy, one shou...
...ommended that patients be monitored clos...
...lapsed Diseas...
...atment for biochemically relapsed myeloma sho...
...ll clinically relapsed patients with symptoms...
...y should be administered on first relapse, though...
...of relapsed multiple myeloma may be continue...
...apies should be taken into consideration when se...
...gous stem cell transplantation, if not received a...
...us of the patients should be assessed...
...isk assessment at the time of relapse should...
...t of other risk factors such as renal insufficien...
...th genetic high-risk disease a triplet com...
...with renal insufficiency, drugs should...
...with plasma cell leukemia or extra medu...
...he IMWG revised response criteria...
...easurable parameters need to be follo...
...onses excluding marrow and imaging should be c...
...ssessment should be performed after...
...orithm On Management of Patients w...
Table 1. Drugs Used in the Management of Pat...
...nostic Criteria for Active Multiple My...
...e 3. Revised International Staging System (R-...
...son of Select Risk Prediction Models Relevant...
...IMWG Response CriteriaHaving trouble viewing table...
...ted Cost of Drugs for Multiple Mye...